Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUBAIN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Mild to moderate pain,Fever
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via glucuronidation; CYP450 isoenzymes are not significantly involved.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 25–30% bound to plasma proteins (mainly albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
4–6 L/kg; indicates extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability is low (<20%) due to extensive first-pass metabolism; IV, IM, and subcutaneous routes provide 100% bioavailability.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl 30-50 m L/min: reduce dose by 50% and administer every 6 hours; Cr Cl <30 m L/min: reduce dose by 75% and administer every 8 hours.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class B: reduce dose by 50% and administer every 6 hours; Child-Pugh Class C: reduce dose by 75% and administer every 8 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Children ≥1 year: 0.1-0.2 mg/kg IV, IM, or SC every 3-6 hours as needed; maximum single dose 20 mg.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 50% of the usual adult dose (5-10 mg) and titrate cautiously; maximum single dose 15 mg due to increased sensitivity and risk of respiratory depression.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of interactions with drugs affecting CYP3A4; risk of serotonin syndrome with concurrent use of serotonergic drugs.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Respiratory depression,Increased intracranial pressure,Hepatic or renal impairment,Biliary tract disease,Concurrent CNS depressants,Opioid dependence (may precipitate withdrawal),Elderly and debilitated patients
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to nalbuphine or any component,Current or suspected opioid dependence (may precipitate acute withdrawal)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions. Avoid grapefruit juice as it may affect metabolism of certain opioids, though no direct evidence with nalbuphine.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy Category C. First trimester: insufficient human data; animal studies show increased skeletal anomalies at high doses. Second and third trimesters: prolonged use may cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use due to risk of respiratory depression in neonate.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in breast milk; M/P ratio unknown. Use caution due to potential for infant sedation and respiratory depression. American Academy of Pediatrics considers use compatible but monitor for drowsiness and feeding difficulties.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No established dose adjustment guidelines. Pregnancy may increase clearance of opioids; however, Nubain (nalbuphine) has not been systematically studied for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration, avoiding chronic use. In labor, use 10–20 mg IV/IM every 3–6 hours as needed; titrate to maternal pain with fetal monitoring.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
NUBAIN (nalbuphine) is a mixed agonist-antagonist opioid; it can precipitate withdrawal in opioid-dependent patients. It has a ceiling effect for respiratory depression, making it safer than pure agonists in high doses. Onset of action is 2-3 minutes IV, 15 minutes IM/SC; duration is 3-6 hours. Reversal of opioid effects may require higher doses of naloxone due to nalbuphine's strong receptor binding.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they can increase side effects like drowsiness or slow breathing.,Do not drive or operate machinery until you know how NUBAIN affects you; it may cause dizziness or drowsiness.,Do not stop abruptly; withdrawal symptoms may occur (anxiety, sweating, nausea).,If you have a history of opioid dependence, inform your doctor; NUBAIN may cause withdrawal symptoms.,Report any signs of allergic reaction (rash, itching, swelling) or difficulty breathing immediately.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUBAIN vs ACEPHEN, answered by our medical review team.
NUBAIN is a Opioid Analgesic that works by Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUBAIN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUBAIN is: 10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUBAIN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUBAIN is classified as Category C. Pregnancy Category C. First trimester: insufficient human data; animal studies show increased skeletal anomalies at high doses. Second and third trimesters: prolonged use may cause. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.